CONCORDE: A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Sponsor

University of Leeds (Other)

Overall Status

Recruiting

CT.gov ID

NCT04550104

Collaborator

University of Manchester (Other), Newcastle University (Other), University of Oxford (Other), The Leeds Teaching Hospitals NHS Trust (Other), Beatson West of Scotland Cancer Centre (Other), University of Glasgow (Other), Velindre NHS Trust (Other), University College London Hospitals (Other), Queen's University, Belfast (Other), University of Sheffield (Other)

200

Enrollment

Location

Arms

73.5

Anticipated Duration (Months)

2.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

CONCORDE is a multi-institution, multi-arm, Phase IB study that will determine the recommended phase II dose (RP2D) and safety profiles of different DNA damage repair inhibitors (DDRis) when given in an open label fashion in combination with fixed dose curative intent radiotherapy (RT) in patients with stage IIB/IIIA/IIIB NSCLC. The RP2D will be evaluated by incorporating the number of observed dose limiting toxicities (DLTs) into a time to event continuous reassessment method (TiTE- CRM) model within each of the experimental arms. TiTE-CRM is used here to take into account longer-term toxicities up to 13.5 months post start of radiotherapy and use these to inform dose escalation decision making.

Condition or Disease	Intervention/Treatment	Phase
Non Small Cell Lung Cancer	Radiation: Radiotherapy Drug: Olaparib Oral Tablet [Lynparza] Drug: AZD1390 Drug: TBD Compound 1 Drug: TBD Compound 2 Drug: TBD Compound 3	Phase 1

Detailed Description

Radiotherapy is an effective treatment for patients with non-small cell lung cancer (NSCLC) that has not spread beyond the chest area. Radiotherapy is used as a curative treatment but unfortunately for most patients the cancer can return. Radiotherapy kills cells by damaging their DNA. Cells have the ability to repair that damage, especially the cells of normal tissue. If DNA repair can be prevented radiotherapy should be more effective causing the cancer cells to die.

The study will use new drugs that affect how cells repair DNA damage, called DNA damage response inhibitors (DDRi). These will be given together with radiotherapy to hopefully improve the effectiveness of radiotherapy. The study will try to find out the most effective and safe dose of this combination treatment. There will be a clinical trial where patients due to have radiotherapy, with the hope of successful treatment that could lead to cure from their cancer or extension of life, will be offered entry onto the study. All patients will receive their radiotherapy, with 3 out of every 4 people also receiving a single DDRi drug alongside this. Both patients and study doctors will know prior to the start of the actual treatment whether a DDRi will be given, and if so which one; no placebos will be used. The patients will be followed closely to check for side effects and to assess how their cancer is responding to treatment. Blood samples will be taken to monitor treatment progress and to try to predict which patients are most likely to benefit from this type of combined treatment.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

200 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

The trial is designed as a randomised Phase I dose escalation platform study, using the TiTE CRM design to find the RP2D of each DDRi with RT combination. At the time of patient identification the treating centre will be informed of the allocated study arm following a pre-specified prioritisation schedule. Consenting participants will be randomised between DDRi with RT or RT only. Patients are not randomised between experimental arms nor will endpoints be compared between experimental arms. RT only participants will be pooled across the platform to provide contemporary data on toxicity.The trial is designed as a randomised Phase I dose escalation platform study, using the TiTE CRM design to find the RP2D of each DDRi with RT combination. At the time of patient identification the treating centre will be informed of the allocated study arm following a pre-specified prioritisation schedule. Consenting participants will be randomised between DDRi with RT or RT only. Patients are not randomised between experimental arms nor will endpoints be compared between experimental arms. RT only participants will be pooled across the platform to provide contemporary data on toxicity.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer

Actual Study Start Date :

Mar 17, 2021

Anticipated Primary Completion Date :

Mar 1, 2023

Anticipated Study Completion Date :

May 1, 2027

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Radiotherapy only	Radiation: Radiotherapy Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
Experimental: Olaparib + radiotherapy	Radiation: Radiotherapy Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday. Drug: Olaparib Oral Tablet [Lynparza] Oral tablet
Experimental: AZD1390 + radiotherapy	Radiation: Radiotherapy Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday. Drug: AZD1390 Oral tablet
Experimental: TBD1 + radiotherapy DDRi to be decided	Radiation: Radiotherapy Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday. Drug: TBD Compound 1
Experimental: TBD2 + radiotherapy DDRi to be decided	Radiation: Radiotherapy Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday. Drug: TBD Compound 2
Experimental: TBD3 + radiotherapy DDRi to be decided	Radiation: Radiotherapy Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday. Drug: TBD Compound 3

Outcome Measures

Primary Outcome Measures

Dose limiting Toxicities [13.5 months after start of radiotherapy]
Dose-limiting toxicities (DLTs), within 13.5 months of starting radiotherapy, in order to establish the Recommended Phase II Dose (RP2D) of each DDRi-RT combination.

Secondary Outcome Measures

Safety and toxicity [2 years after end of RT]
Safety will be reported based on the occurrence of SAEs, SARs and SUSARs. Toxicity will be reported based on adverse events, as graded by CTCAE V5.0, and determined by routine clinical assessments at each centre.
Treatment compliance [End of trial treatment (DDRi and RT)]
Treatment compliance will be measured by overall radiotherapy treatment time and delays, omissions and reductions to treatment doses (both DDRi and RT).
Best overall response [2 years after end of RT]
Best overall response will be measured as the best response (complete response, partial response or stable disease) recorded until disease progression, reported up to 2 years post-RT. This will be assessed using RECIST 1.1
Disease control [2 years after end of RT]
This will be assessed using the Green Criteria. Disease Control includes either the complete disappearance of all evidence of malignant disease or residual radiographic abnormalities assessed by chest CT scan at 3 and 6 months after completion of RT, which then remains stable for an additional 6 months or more and which then qualifies as controlled local disease.
Progression-free survival [2 years post-RT]
Participants who have not progressed at the time of analysis will be censored at the last date they were known to be alive and progression free
Overall survival [2 years post-RT]
Participants who have not died at the time of analysis will be censored at the last date they were known to be alive
Changes in Health Related Quality of Life [2 years after end of RT]
Health Related Quality of Life will be determined using EORTC QLQ-C30, IL-73 and IL-74
Objective response rate [2 years after end of RT]
Objective response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy. The proportion of patients with evaluable scans that achieve at least a partial response, as defined by RECIST v1.1(31), will be presented with 95% confidence intervals.
Changes in tumour size during and following treatment with DDRi-RT compared to RT alone. [2 years after end of RT]

Other Outcome Measures

Assessment of mutations in components of DDR pathway in archival tumour and cfDNA prior to therapy [2 years after end of RT]
Exploratory endpoint
Assessment of T cells within the archival tumour specimens [2 years after end of RT]
Exploratory endpoint
Changes in cfDNA during and following treatment with DDRi-RT compared to RT alone. [2 years after end of RT]
Exploratory endpoint
Changes in circulating biomarkers of cardiac and respiratory toxicity during and following treatment with DDRi-RT compared to RT alone. [3 months post end of RT]
Exploratory endpoint
Changes in circulating peripheral T cell sub-sets during and following treatment with DDRi-RT compared to RT alone. [2 years after end of RT]
Exploratory endpoint
Changes in lung parenchyma during and following treatment with DDRi-RT compared to RT alone. [2 years after end of RT]
Exploratory endpoint

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically or cytologically confirmed NSCLC
Not suitable for concurrent chemoradiotherapy/surgery due to tumour or patient factors
Stage IIB and IIIA/IIIB (TNM 8th Edition) planned to receive RT at curative intent doses (i.e. 60Gy) as part of treatment plan (either with or without induction chemotherapy)
Patient considered suitable for radical RT by the local lung cancer multidisciplinary team and a clinical oncologist
If chemotherapy has been given previously, the maximum interval between the last day of chemotherapy and the start of RT <8 weeks.
Age ≥18
Life expectancy estimated to be greater than 6 months.
Performance status (ECOG) 0 or 1.
MRC dyspnoea score <3.
Forced expiratory volume in one second (FEV1) ≥ 40% predicted and diffusing capacity of the lungs for carbon monoxide (DLCO) ≥40% predicted;
Patient must be fully informed about the study and have signed the informed consent form
Patient must be willing and able to comply with the protocol, have mental capacity and (if relevant) use effective contraception throughout treatment and for 28 days after treatment completion (for women) and 3 months after treatment completion (for men) (or comply with more stringent contraceptive requirements if prescribed in the relevant study-arm protocol).
Adequate organ function within 28 days prior to confirmation of eligibility and 7 days of study treatment as defined in master protocol

Exclusion Criteria:

Mixed non-small cell and small cell tumours
Confirmed progressive disease during induction chemotherapy
Participation in a study of an investigational agent or using an investigational device within 4 weeks prior to the anticipated start of treatment
Current or previous malignant disease which may impact on a patient's estimated life expectancy
History of interstitial pneumonitis
Prior thoracic radiotherapy (excluding patients that have had RT for breast cancer providing that the overlap is minimal as per local investigators discretion or as discussed and agreed by CI as required)
Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year. If prior therapy in lifetime, then exclude if history of pulmonary toxicities from administration. Patients who have received treatment with nitrosoureas (e.g., carmustine, lomustine) in the year before study entry without experiencing lung toxicity are allowed on study.
Mean resting corrected QT interval (QTcF) >470 msec obtained from 3 electrocardiograms (ECGs) (QTc interval will be calculated using Fridericia's formula).
Received a prior autologous or allogeneic organ or tissue transplantation.
Patients unable to swallow orally administered medications or chronic gastrointestinal (GI) disease likely to interfere with absorption of IMP in the opinion of the treating investigator (e.g. malabsorption syndrome, resection of the small bowel, poorly controlled inflammatory bowel disease etc).
Grade 2 or higher peripheral sensory neuropathy.
Known positive test for human immunodeficiency virus (HIV), active hepatitis B or C infection (new test not mandated for trial entry).
Positive pregnancy test (at eligibility assessment for women of childbearing potential) or breast-feeding women.
Patients with persistent toxicities (>CTCAE grade 2) caused by previous cancer therapy, excluding alopecia.
Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.
Major surgery within 2 weeks of confirmation of eligibility.
Patients considered a poor medical risk by the investigator due to a serious, uncontrolled medical disorder, non-malignant system disease or active uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, uncontrolled hypertension, uncontrolled atrial fibrillation, active bleeding, recent (within 3 months) myocardial infarction, major seizure, active COVID-19, any psychiatric disorder that prohibits obtaining informed consent.
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (eg, ulcerative colitis or Crohn's disease), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc)). The following are exceptions to this criterion:
Patients with vitiligo or alopecia.
Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
Any chronic skin condition that does not require systemic therapy.
Patients without active disease in the last 5 years at enrolment may be included but only after consultation with the CI/Study arm-lead.
Patients with coeliac disease controlled by diet alone.
Exclusions as described in the relevant study arm protocol

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust	Newcastle Upon Tyne		United Kingdom

Investigators

Principal Investigator: Alastair Greystoke, MB ChB, MSc, PhD, Newcastle University
Principal Investigator: Corinne Faivre-Finn, MD, PhD, University of Manchester

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:

University of Leeds

ClinicalTrials.gov Identifier:

NCT04550104

Other Study ID Numbers:

MO20/118073
2020-000206-28
282001
A28890

First Posted:

Sep 16, 2020

Last Update Posted:

Aug 6, 2021

Last Verified:

Jul 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD: